Literature DB >> 20809972

Recurrent myelitis after allogeneic stem cell transplantation. Report of two cases.

Martin Voss1, Felix Bischof.   

Abstract

BACKGROUND: Allogeneic and autologous haematopoietic stem cell transplantation are established treatment options for haematological malignancies and may possibly be employed to treat a range of genetic and autoimmune diseases. CASE
PRESENTATION: We report two patients who developed an acute myelitis within their thoracic spinal cord after allogeneic stem cell transplantation. Myelitis in these patients was not related to graft versus host disease or immune reconstitution and was responsive to intravenous methylprednisolone and cyclophosphamide.
CONCLUSIONS: Myelitis is a possibly disabling consequence of haematopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809972      PMCID: PMC2936883          DOI: 10.1186/1471-2377-10-76

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


  6 in total

1.  Central nervous system immune reconstitution inflammatory syndrome (IRIS) after hematopoietic SCT.

Authors:  L Airas; M Päivärinta; M Röyttä; J Karhu; M Kauppila; M Itälä-Remes; K Remes
Journal:  Bone Marrow Transplant       Date:  2009-08-17       Impact factor: 5.483

Review 2.  Neurological complications of hematopoietic cell transplantation.

Authors:  Albert Saiz; Francesc Graus
Journal:  Semin Neurol       Date:  2004-12       Impact factor: 3.420

3.  Spectrum and prognosis of neurologic complications after hematopoietic transplantation.

Authors:  C Denier; J-H Bourhis; C Lacroix; S Koscielny; J Bosq; R Sigal; G Said; D Adams
Journal:  Neurology       Date:  2006-12-12       Impact factor: 9.910

Review 4.  Stem cell transplantation for neurodegenerative diseases.

Authors:  Anne E Rosser; Rike Zietlow; Stephen B Dunnett
Journal:  Curr Opin Neurol       Date:  2007-12       Impact factor: 5.710

5.  Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

Authors:  Marcos de Lima; Daniel Couriel; Peter F Thall; Xuemei Wang; Timothy Madden; Roy Jones; Elizabeth J Shpall; Munir Shahjahan; Betty Pierre; Sergio Giralt; Martin Korbling; James A Russell; Richard E Champlin; Borje S Andersson
Journal:  Blood       Date:  2004-04-08       Impact factor: 22.113

6.  Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis.

Authors:  T Mondria; C H J Lamers; P A W te Boekhorst; J W Gratama; R Q Hintzen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-01-25       Impact factor: 10.154

  6 in total
  6 in total

1.  Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease.

Authors:  Anna Maria Delios; Marc Rosenblum; Ann A Jakubowski; Lisa M DeAngelis
Journal:  J Neurooncol       Date:  2012-08-23       Impact factor: 4.130

2.  Case report: Central nervous system involvement of human graft versus host disease: Report of 7 cases and a review of literature.

Authors:  Mathilde Ruggiu; Wendy Cuccuini; Karima Mokhtari; Véronique Meignin; Régis Peffault de Latour; Marie Robin; Flore Sicre de Fontbrune; Aliénor Xhaard; Gérard Socié; David Michonneau
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

3.  A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.

Authors:  Joyutpal Das; Atta Gill; Christine Lo; Natalie Chan-Lam; Siân Price; Stephen B Wharton; Helen Jessop; Basil Sharrack; John A Snowden
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

Review 4.  Central Nervous System-related Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Yuta Kaito; Shunsuke Yui; Kazuki Inai; Daishi Onai; Ryosuke Kinoshita; Satoshi Yamanaka; Muneo Okamoto; Ryuichi Wada; Ryuji Ohashi; Koiti Inokuchi; Hiroki Yamaguchi
Journal:  Intern Med       Date:  2021-10-15       Impact factor: 1.271

Review 5.  Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

Review 6.  Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Nataliya Prokopenko Buxbaum; Steven Z Pavletic
Journal:  Front Immunol       Date:  2020-08-25       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.